SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected hand-foot-mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, mumps, etc.
The COVID-19 vaccine, CoronaVac?, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive?, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive?, is an innovative vaccine under "Category 1 Preventative Biological Products" and commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO.
SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1?, which has supplied the Chinese government's vaccination campaign and stockpiling program.The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu?, to the Chinese government stockpiling program.
SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities.
SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations.
Grant Thornton Zhitong Certified Public Accountants LLP
Pacific Stock Transfer Company
Principal Executive Office
No. 39, Shangdi Xi Road, Haidian District, Beijing 100085, P.R.C.